Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2015

View Archived Issues

Grant awarded to Euroscreen for research into GPCR-targeted neurodegenerative disease treatments

Isis Pharmaceuticals advances ISIS-SMNRx in infants with spinal muscular atrophy

VolitionRx initiates Belgian study to investigate NuQ for detection of prostate cancer

ValiRx raises funding to support key programs

Pharmacokinetics of topical umeclidinium for hyperhidrosis determined

New development strategy formulated for Diabecell

Norgine and Navidea sign European commercialization and distribution agreement for Lymphoseek

RaQualia signs collaboration agreement with the Nagoya University

PoC study results support efficacy of lonafarnib in patients with HDV

Novel acylguanidine-based small molecule inhibits HIV-1 replication

Epigenetic inhibitor induces resensitization to irinotecan-based therapies

R-Tech Ueno regains all licenses to unoprostone, reports phase III data

Targacept and Catalyst Biosciences merge to create protease-based hemostasis company

ContraVir Pharmaceuticals to begin pivotal phase III study of FV-100

CTI BioPharma and Baxter report topline data from phase III Persist-1 trial of pacritinib

Indian CSIR patents new anticancer agents

Mallinckrodt Pharmaceuticals to expand hospital growth platform with Ikaria acquisition

Allergan discloses S1P1 modulators

University of Warsaw divulges neuropilin-1 antagonists

Heat Biologics receives FDA fast track designation for HS-410 in combination with BCG

Substance abuse candidate GS-6637 well tolerated in healthy volunteers

Merck & Co. patents LRRK2 inhibitors

Vanderbilt University patent describes muscarinic M4 receptor PAMs

Domain Therapeutics launches Kaldi Pharma to develop its adenosine programs

Alfa Wassermann and Sigma-Tau to create new company

Rosuvastatin/ezetimibe fixed-dose combination bioequivalent to coadministration of each drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...